GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2015 financial and operating results prior to the open of U.S. financial markets on Monday, February 29, 2016.
Management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.
Conference call details are as follows:
Conference call replay:
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.